Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.

@article{Vogelbaum2007ConvectionenhancedDO,
  title={Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results.},
  author={Michael A. Vogelbaum and John H. Sampson and Sandeep M Kunwar and Susan M. Chang and Mark E. Shaffrey and Anthony L. Asher and Frederick F. Lang and David Croteau and Kristen N Parker and Amy Y. Grahn and Jeffrey W. Sherman and Syed Rafat Husain and Raj K. Puri},
  journal={Neurosurgery},
  year={2007},
  volume={61 5},
  pages={1031-7; discussion 1037-8}
}
OBJECTIVE Cintredekin besudotox (CB), a recombinant cytotoxin consisting of interleukin-13 and truncated Pseudomonas exotoxin, binds selectively to interleukin-13R alpha2 receptors overexpressed by malignant gliomas. This study assessed the safety of CB administered by convection-enhanced delivery followed by standard external beam radiation therapy (EBRT) with or without temozolomide (Temodar; Schering-Plough, Kenilworth, NJ) in patients with newly diagnosed malignant gliomas. METHODS After… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…